Telix Pharmaceuticals' (ASX:TLX) unaudited revenue for the first quarter reached AU$186 million, an increase of 62% from AU$115 million in the year-ago period, according to a Tuesday filing with the Australian bourse.
This comprised AU$151 million from global sales of Illuccix and AU$33 million from RLS Radiopharmacies, which was acquired in January.
The biopharmaceutical company reaffirmed its FY2025 revenue guidance of AU$770 million to AU$800 million. It noted that this will be updated "at the appropriate time" to take into account reimbursement for Gozellix in the US and Illuccix in ex-US markets, per the filing.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。